Alto Neuroscience (ANRO) Change in Accured Expenses (2023 - 2026)

Alto Neuroscience has reported Change in Accured Expenses for 4 years, with the latest figure at -$1.8 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 35.1% year-over-year to -$1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $659000.0 (down 26.78% YoY) and the FY2025 annual result came in at -$289000.0, down 107.21% from the prior year.
• Change in Accured Expenses declined to -$1.8 million in Q1 2026 per ANRO's latest filing, from $1.7 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $1.7 million in Q4 2025 and troughed at -$2.7 million in Q1 2025.
• A 4-year average of $123692.3 and a median of $406000.0 in 2024 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 323.6% in 2025, down 765.27% in 2025.
• Over 4 years, Change in Accured Expenses stood at -$500000.0 in 2023, then jumped by 182.2% to $411000.0 in 2024, then soared by 323.6% to $1.7 million in 2025, then slumped by 200.69% to -$1.8 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.8 million, $1.7 million, and $208000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.